Gracell Biotechnologies Inc reports results for the quarter ended in March - Earnings Summary

Gracell Biotechnologies

16/05/2022 14:32

* Gracell Biotechnologies Inc  GRCL.OQ  reported a quarterly
adjusted loss of 35 cents​​ per share for the quarter ended in
March. The mean expectation of three analysts for the quarter
was for a loss of 21 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Gracell Biotechnologies Inc's reported EPS for the quarter
was a
loss of 35 cents​.
    * The mean earnings estimate of analysts had risen by
about 47.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Gracell Biotechnologies Inc shares had risen by 42.9% this
quarter and lost 44.9% so far this year.
    * The company reported a quarterly loss of $25.02 million.
    * Wall Street's median 12-month price target for Gracell
Biotechnologies Inc is $23.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated May 16 at 01:32 p.m.  ​All
figures in US dollars unless otherwise stated